Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 24295618)

1.

Functional imaging of dopaminergic neurotransmission in Tourette syndrome.

Segura B, Strafella AP.

Int Rev Neurobiol. 2013;112:73-93. doi: 10.1016/B978-0-12-411546-0.00003-2.

PMID:
24295618
2.

Extrastriatal dopaminergic dysfunction in tourette syndrome.

Steeves TD, Ko JH, Kideckel DM, Rusjan P, Houle S, Sandor P, Lang AE, Strafella AP.

Ann Neurol. 2010 Feb;67(2):170-81. doi: 10.1002/ana.21809.

PMID:
20225192
3.

Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.

Steeves TD, Fox SH.

Prog Brain Res. 2008;172:495-513. doi: 10.1016/S0079-6123(08)00924-2. Review.

PMID:
18772048
4.

Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome.

Worbe Y, Marrakchi-Kacem L, Lecomte S, Valabregue R, Poupon F, Guevara P, Tucholka A, Mangin JF, Vidailhet M, Lehericy S, Hartmann A, Poupon C.

Brain. 2015 Feb;138(Pt 2):472-82. doi: 10.1093/brain/awu311. Epub 2014 Nov 11.

5.

Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Wong DF, Brasić JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA.

Neuropsychopharmacology. 2008 May;33(6):1239-51. Epub 2007 Nov 7.

6.

Microstructure assessment of grey matter nuclei in adult tourette patients by diffusion tensor imaging.

Neuner I, Kupriyanova Y, Stöcker T, Huang R, Posnansky O, Schneider F, Shah NJ.

Neurosci Lett. 2011 Jan 3;487(1):22-6. doi: 10.1016/j.neulet.2010.09.066. Epub 2010 Oct 1.

PMID:
20888391
7.

White-matter abnormalities in Tourette syndrome extend beyond motor pathways.

Neuner I, Kupriyanova Y, Stöcker T, Huang R, Posnansky O, Schneider F, Tittgemeyer M, Shah NJ.

Neuroimage. 2010 Jul 1;51(3):1184-93. doi: 10.1016/j.neuroimage.2010.02.049. Epub 2010 Feb 24.

PMID:
20188196
8.

Neuromodulation in Tourette syndrome: dopamine and beyond.

Buse J, Schoenefeld K, Münchau A, Roessner V.

Neurosci Biobehav Rev. 2013 Jul;37(6):1069-84. doi: 10.1016/j.neubiorev.2012.10.004. Epub 2012 Oct 17. Review.

PMID:
23085211
9.

Functional immaturity of cortico-basal ganglia networks in Gilles de la Tourette syndrome.

Worbe Y, Malherbe C, Hartmann A, Pélégrini-Issac M, Messé A, Vidailhet M, Lehéricy S, Benali H.

Brain. 2012 Jun;135(Pt 6):1937-46. doi: 10.1093/brain/aws056. Epub 2012 Mar 19.

10.

Distinct structural changes underpin clinical phenotypes in patients with Gilles de la Tourette syndrome.

Worbe Y, Gerardin E, Hartmann A, Valabrégue R, Chupin M, Tremblay L, Vidailhet M, Colliot O, Lehéricy S.

Brain. 2010 Dec;133(Pt 12):3649-60. doi: 10.1093/brain/awq293. Epub 2010 Oct 19.

11.

Altered mesolimbocortical and thalamic dopamine in Tourette syndrome.

Gilbert DL, Christian BT, Gelfand MJ, Shi B, Mantil J, Sallee FR.

Neurology. 2006 Nov 14;67(9):1695-7.

PMID:
17101911
12.

Glutamatergic modulatory therapy for Tourette syndrome.

Singer HS, Morris C, Grados M.

Med Hypotheses. 2010 May;74(5):862-7. doi: 10.1016/j.mehy.2009.11.028. Epub 2009 Dec 21.

PMID:
20022434
13.

Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder.

Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN.

Eur Neuropsychopharmacol. 2013 Nov;23(11):1423-31. doi: 10.1016/j.euroneuro.2013.05.012. Epub 2013 Jul 19.

14.

Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.

Lerner A, Bagic A, Simmons JM, Mari Z, Bonne O, Xu B, Kazuba D, Herscovitch P, Carson RE, Murphy DL, Drevets WC, Hallett M.

Brain. 2012 Jun;135(Pt 6):1926-36. doi: 10.1093/brain/aws104. Epub 2012 May 10.

15.

Dopamine and the diseased brain.

Kienast T, Heinz A.

CNS Neurol Disord Drug Targets. 2006 Feb;5(1):109-31. Review.

PMID:
16613557
16.

Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.

Albin RL, Koeppe RA, Wernette K, Zhuang W, Nichols T, Kilbourn MR, Frey KA.

Neurology. 2009 Apr 21;72(16):1390-6. doi: 10.1212/WNL.0b013e3181a187dd.

17.

Bithalamical deep brain stimulation in tourette syndrome is associated with reduction in dopaminergic transmission.

Vernaleken I, Kuhn J, Lenartz D, Raptis M, Huff W, Janouschek H, Neuner I, Schaefer WM, Gründer G, Sturm V.

Biol Psychiatry. 2009 Nov 15;66(10):e15-7. doi: 10.1016/j.biopsych.2009.06.025. Epub 2009 Aug 26. No abstract available.

PMID:
19709645
18.

Pharmacological animal models of Tourette syndrome.

Bronfeld M, Israelashvili M, Bar-Gad I.

Neurosci Biobehav Rev. 2013 Jul;37(6):1101-19. doi: 10.1016/j.neubiorev.2012.09.010. Epub 2012 Oct 23. Review.

PMID:
23089155
19.

[Tourette's syndrome - a review].

Riederer F, Stamenkovic M, Schindler SD, Kasper S.

Nervenarzt. 2002 Sep;73(9):805-19. Review. German.

PMID:
12215871
20.

Neurobiology of tourette syndrome: current status and need for further investigation.

Felling RJ, Singer HS.

J Neurosci. 2011 Aug 31;31(35):12387-95. doi: 10.1523/JNEUROSCI.0150-11.2011.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk